Former Goldman Sachs Managing Director Andrew Pucher joins Tilray
to lead the company’s global corporate development activity, including
M&A and corporate investments
NANAIMO, British Columbia--(BUSINESS WIRE)--Mar. 13, 2019--
Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis
production, research, cultivation and distribution, announces the
expansion of its global senior leadership team with the appointment of
Andrew Pucher as Chief Corporate Development Officer. In his new role,
Andrew will lead Tilray’s corporate development function, including the
team that is responsible for M&A and corporate investments. He will be
based in Toronto, ON, and report to CEO Brendan Kennedy.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190313005090/en/
Andrew Pucher, Chief Corporate Development Officer, Tilray (Photo: Business Wire)
Andrew joins Tilray from Goldman Sachs, where he was a Managing Director
and most recently served as Head of Canadian Diversified Investment
Banking, which included coverage of the Canadian cannabis industry.
Previously, he was a member of Goldman Sachs’ Global Healthcare
Investment Banking Group in New York, where he advised on more than $200
billion in announced M&A and financing transactions, with a focus on the
biopharmaceutical sector. Andrew is a graduate of Simon Fraser
University and earned a JD/MBA from York University.
Brendan Kennedy, Tilray’s CEO, said, “We’re pleased to welcome Andrew to
our senior leadership team to execute strategic transactions that will
further accelerate Tilray’s long-term global growth. Andrew shares our
commitment to a disciplined, strategic approach in pursuing inorganic
growth opportunities. His transaction experience and industry knowledge
will be valuable as we work to capitalize on the many strategic
opportunities available to us and continue to pursue the disruptive
potential of cannabis across industries including pharmaceuticals,
alcohol, consumer goods, functional food and beverage, retail and
nutraceuticals.”
Recent Tilray transactions and partnerships include: forming a global
partnership with Sandoz, a division of Novartis, to distribute its
medical products; establishing a 50/50 joint venture with AB InBev, the
world’s largest brewer, to develop THC and CBD beverages; signing an
agreement to produce THC and CBD products for Authentic Brands Group
portfolio of brands, which includes Muhammed Ali, Nine West, Spyder ski
gear, Prince tennis wear, Marilyn Monroe, Juicy Couture and Elvis
Presley; acquiring Natura Naturals Holdings, thereby increasing its
cannabis supply; and most recently, announcing the acquisition of
Manitoba Harvest, the world’s largest hemp company, accelerating the
company’s entry into the natural foods space with hemp and CBD-infused
food and wellness products for North America.
Over the past several months, Tilray has announced appointments to its
senior leadership team, with executives from world-leading brands:
Sascha Mielcarek joined Tilray from Grünenthal to become Managing
Director, Europe; Greg Christopher joined from Nestle to become Tilray’s
EVP of Operations; Rita Seguin came on board from Diageo to be Tilray’s
EVP of Human Resources; Dara Redler, Tilray’s General Counsel worked
previously at The Coca-Cola Company; and Charlie Cain as VP of Retail
came from Starbucks Corporation.
About Tilray®
Tilray (NASDAQ:TLRY) is a global pioneer in the research, cultivation,
production and distribution of cannabis and cannabinoids currently
serving tens of thousands of patients and consumers in twelve countries
spanning five continents.
Cautionary Note Regarding Forward-looking Statements
This press release contains “forward-looking statements” within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
“forward-looking information” within the meaning of Canadian securities
laws, or collectively, forward-looking statements. Forward-looking
statements in this press release may be identified by the use of words
such as, “may”, “would”, “could”, “will”, “likely”, “expect”,
“anticipate”, “believe, “intend”, “plan”, “forecast”, “project”,
“estimate”, “outlook” and other similar expressions and include
statements relating to the growth and global success of the Tilray.
Forward-looking statements are not a guarantee of future performance and
are based upon a number of estimates and assumptions of management in
light of management’s experience and perception of trends, current
conditions and expected developments, as well as other factors that
management believes to be relevant and reasonable in the circumstances,
including assumptions in respect of current and future market
conditions, the current and future regulatory environment and future
approvals and permits. Actual results, performance or achievement could
differ materially from that expressed in, or implied by, any
forward-looking statements in this press release, and, accordingly, you
should not place undue reliance on any such forward-looking statements
and they are not guarantees of future results. Forward-looking
statements involve significant risks, assumptions, uncertainties and
other factors that may cause actual future results or anticipated events
to differ materially from those expressed or implied in any
forward-looking statements. Please see the heading “Risk Factors” in
Tilray’s Quarterly Report on Form 10-Q, which was filed with the
Securities and Exchange Commission and Canadian securities regulators on
November 14, 2018, for a discussion of the material risk factors that
could cause actual results to differ materially from the forward-looking
information. Tilray does not undertake to update any forward-looking
statements that are included herein, except in accordance with
applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005090/en/
Source: Tilray, Inc.
Media: Chrissy Roebuck, 1-833-206-8161,news@tilray.com
Investors:
Katie Turner, +1-646-277-1228, Katie.turner@icrinc.com
